Suggestions
Eric Easom
CEO & Co-Founder at AN2 Therapeutics
Professional Background
Eric Easom is an accomplished leader in the biotechnology sector, with a specific focus on infectious diseases and global health. He has dedicated his career to tackling some of the most pressing health issues facing the world today, particularly those related to neglected tropical diseases. As the CEO and Co-Founder of AN2 Therapeutics, Inc., Eric combines his extensive knowledge of business development with a passion for innovative healthcare solutions. His hands-on leadership style and insightful strategic thinking have made a significant impact within the organizations he has led.
Eric's experience spans various roles and responsibilities, demonstrating his versatility and deep understanding of the biotechnology landscape. Before establishing AN2 Therapeutics, he served as the Vice President of Neglected Diseases at Anacor Pharmaceuticals, where he was instrumental in driving initiatives aimed at alleviating the burden of overlooked diseases affecting millions globally. His prior roles include Sr. Director of Business Development and Marketing at InteKrin Therapeutics, Inc., and Director of Marketing at MedImmune, highlighting his prowess in product development, marketing strategies, and research and development in the biotechnology domain.
Education and Achievements
Eric's academic background is robust, with degrees that reflect his technical and business acumen. He earned his MBA in Marketing and Finance from the prestigious Kelley School of Business at Indiana University, complementing his foundational studies in Electrical Engineering, for which he holds both a Master’s and a Bachelor’s degree from the University of Louisville. This unique combination of engineering and business education allows Eric to bridge the gap between science and commerce, driving innovations that not only enhance product efficacy but are also market-ready.
Throughout his career, Eric has held influential positions on various boards, including the Chagas Disease Foundation and the Infectious Disease Research Institute. His tenure as Chair of the Board at the Infectious Disease Research Institute reflects his commitment to advancing research in infectious diseases while fostering collaboration among experts and organizations in the field. Eric's ability to bring together diverse stakeholders is one of his key strengths, enabling him to drive initiatives that align with both scientific needs and market demands.
Achievements
Eric's career is marked by numerous achievements that exemplify his leadership, strategic vision, and dedication to public health. Under his guidance, AN2 Therapeutics, Inc. has positioned itself as a frontrunner in developing therapies for neglected tropical diseases, working on innovative solutions that aim to improve health outcomes for populations at risk. Eric's experience in non-profit leadership also plays a crucial role in his current endeavors, as he actively seeks partnerships and collaborations that enhance the reach and effectiveness of initiatives aimed at combating infectious diseases globally.
Apart from his corporate endeavors, Eric has also contributed to non-dilutive fundraising efforts, leveraging his expertise to secure funding that supports research and development in the biotech space. This experience is critical in navigating the complexities of fundraising in an industry where financial resources can significantly influence innovation and accessibility to treatments. As a member of various boards, Eric continues to advocate for initiatives that encourage research, public awareness, and the development of effective treatments for neglected diseases.
Eric Easom's multifaceted career reflects a steadfast commitment to improving global health through innovation in biotechnology. His leadership not only drives the success of AN2 Therapeutics but also inspires future generations of professionals in the biopharmaceutical sector to prioritize health equity and scientific advancement. Through his dedication, he stands as a key figure in the ongoing fight against infectious diseases, fostering alliances that empower organizations to overcome challenges and create meaningful change in the lives of those who are most vulnerable.